Immunotherapy for prostate cancer: Canadian working group presents the current status

In NATURE REVIEWS Urology, a Canadian working group presented the current status of immunotherapy for prostate cancer in a review article: "Potentiating prostate cancer immunotherapy with oncolytic viruses." They particularly emphasized the effect of oncolytic viruses. They also cited a case study we conducted and mentioned the IOZK therapy method with electrohyperthermia, Newcastle disease virus, and dendritic cell-based vaccination. "In addition, a case study reports on the development of prostate cancer-specific T-cell immune responses and long-term remission of metastatic castration-resistant prostate cancer after treatment with local hyperthermia, Newcastle disease virus, and dendritic cell-based vaccination." (p. 10)

The article concludes on an optimistic note: "Ultimately, the undermining of immunosuppression induced by oncolytic viruses promotes immunity to the tumor. In addition, treatments with oncolytic viruses can enhance the effect of complementary cancer therapies [and] potentially lead to better outcomes for patients than those that can be achieved by either treatment alone. The supportive immunological properties of oncolytic viruses, in addition to their oncolytic capabilities, are a promising approach for the next breakthrough in immunotherapy for prostate cancer."

In 2014, NATURE was the world's most cited interdisciplinary scientific journal and the journal with the highest impact factor in its category. In addition, alongside the US journal SCIENCE, it is the world's most respected journal for natural sciences.